Latest / Stock Movers / Concentrix Falls, Jefferies Mixed, ImmunityBio Down as FDA Issues Warning Letter on Cancer Claims
Transcript
- 0:02Speaker 1: Bloomberg Audio Studios, Podcasts, Radio News, The.
- 0:08Speaker 2: Stock Movers Report, your roundup of companies making moves in
- 0:12Speaker 2: the stock market. Harnessing the power of Bloomberg Data.
- 0:16Speaker 3: Stake a look at some of the stocks on the
- 0:18Speaker 3: move today. We can do that with avanon her now
- 0:21Speaker 3: Bloomberg News. She joins us here in study Avalon, What
- 0:23Speaker 3: are you looking at?
- 0:23Speaker 1: Yeah, we can go ahead and start off with concentrics
- 0:25Speaker 1: stutsticker cnxseed down about twenty three percent to hit a
- 0:29Speaker 1: record low. That's after a firm second quarter forecast was
- 0:32Speaker 1: weaker than expected. It's adjusted earnings for share guidance missed expectations,
- 0:36Speaker 1: and also the midpoint of its revenue range also fell
- 0:39Speaker 1: short of what investors are expecting, which is kind of
- 0:41Speaker 1: poorly time, considering investors already have a ton of questions
- 0:44Speaker 1: about what structural threats AI will pose to its business.
- 0:48Speaker 1: All right, Next up on your list, yes, Jeffreys ticker JEF,
- 0:51Speaker 1: which is up about three point seven percent. That's after
- 0:54Speaker 1: The Financial Times reported a little bit earlier today that
- 0:56Speaker 1: the Japan based bank SMFG is working on plans for
- 1:00Speaker 1: possible Jeffries buy out. It's kind of interesting timing considering
- 1:04Speaker 1: Jeffries has been under a lot of pressure this year,
- 1:06Speaker 1: considering all of the credit risk that the company has
- 1:09Speaker 1: been caught up in. I'm thinking about like first brands
- 1:11Speaker 1: market financial solutions. But before this news it was down
- 1:14Speaker 1: about thirty six percent this year. And Bloomberg Co Intelligence
- 1:17Speaker 1: is actually out with a note saying that the potential
- 1:19Speaker 1: takeover by SMFG appears more opportunistic as opposed to imminent,
- 1:23Speaker 1: as we continue to report that there are no active talks.
- 1:27Speaker 3: And that bank already owns I looked it up on
- 1:29Speaker 3: the bloomber turmil about four and a half percent of
- 1:30Speaker 3: Jeffrey's already, So this might be an opportunity to take
- 1:33Speaker 3: advantage of some weakness and up that stake here. Jeffries is,
- 1:36Speaker 3: having competed against them for many years, are very very
- 1:38Speaker 3: good of what they do. They have their niches and
- 1:41Speaker 3: they hire and through resources that those niches, and they
- 1:43Speaker 3: compete well.
- 1:44Speaker 1: One more, yes, Immunity Bio that's ticker IBRX, thinking about
- 1:48Speaker 1: twenty two percent for its biggest tumble since twenty twenty four.
- 1:51Speaker 1: That's after the FDA issued a warning letter to the
- 1:53Speaker 1: biotech for false and potentially misleading promotion of its bladder
- 1:56Speaker 1: cancer drug and Ktiva issue was a recent TV add
- 2:00Speaker 1: and also the firm's billionaire executive chairman Patrick Sounschung's rhetoric
- 2:04Speaker 1: on the Sean Spicer Show. You said the drug could
- 2:07Speaker 1: treat all cancers. However, it's currently only approved for a
- 2:10Speaker 1: very specific kind of bladder cancer. Still worth noting that
- 2:13Speaker 1: before today the stock was up three hundred and seventy
- 2:15Speaker 1: five percent this year, so I don't think people are
- 2:19Speaker 1: gonna be that worried.
- 2:20Speaker 2: The stock movers report from Bloomberg Radio. Check back with
- 2:24Speaker 2: us throughout the day for the latest roundup of companies
- 2:27Speaker 2: making news on Wall Street and for the latest market
- 2:30Speaker 2: moving headlines. Listen to Bloomberg Radio Live, catch us on YouTube,
- 2:35Speaker 2: Bloomberg dot com, and on Applecarplay and Android Auto with
- 2:38Speaker 2: the Bloomberg Business app.